Urate has emerged as a promising target for neuroprotection based on epidemiological observations, preclinical models, and early clinical trial results in multiple neurologic diseases, including Parkinson's disease (PD). This study investigates the astrocytic mechanism of urate's neuroprotective effect. Targeted biochemical screens of conditioned medium from urate-versus vehicle-treated astrocytes identified markedly elevated glutathione (GSH) concentrations as a candidate mediator of urate's astrocyte-dependent neuroprotective effects. Urate treatment also induced the nuclear translocation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein and transcriptional activation of its key target genes in primary astrocytic cultures. Urate's neuroprotective effect was attenuated when GSH was depleted in the conditioned media either by targeting its synthesis or release by astrocytes. Overall, these results implicate GSH as the extracellular astrocytic factor mediating the protective effect of urate in a cellular model of PD. These results also show that urate can employ a novel indirect neuroprotective mechanism via induction of the Nrf2 signaling pathway, a master regulator of the response to oxidative stress, in astrocytes.
Introduction
Urate (2,6,8-trioxy-purine; a.k.a. uric acid) has been gaining momentum as a promising candidate therapeutic target for people with Parkinson's disease (PD) based on its antioxidant and neuroprotective properties, and on its identification as a predictor of a reduced PD risk and a favorable rate of disease progression (Cipriani et al., 2010) . Several groups including ours have documented protective properties of urate in cellular and rodent models of PD and other neurodegenerative diseases (Bakshi et al., 2015) . In dopaminergic cell lines, urate blocked cell death and oxidative stress induced by 6-hydroxydopamine (6-OHDA), dopamine or rotenone (Zhu et al., 2012; Jones et al., 2000; Duan et al., 2002) . Urate at physiologically relevant concentrations enhanced function and survival of dopaminergic neurons in primary cultures of rat ventral mesencephalon (Guerreiro et al., 2009) . Urate also confers protection in various cellular models of neurotoxicity beyond that of PD. Urate protected cultured spinal cord or hippocampal neurons from excitotoxic (glutamate-induced) (Yu et al., 1998; Du et al., 2007) or nitrosative (peroxynitrite-induced) cell death (Scott et al., 2005) . Similarly, in intact animals urate protects these neurons from ischemic brain or compressive spinal cord injuries (Yu et al., 1998; Scott et al., 2005) .
The neuroprotective effects of urate have also been evaluated in vivo in rodent models of PD, and was found to attenuate 6-OHDA toxicity (Gong et al., 2012) . Similarly, our group found that mice with a urate oxidase gene (UOx) knockout have elevated brain urate levels and are resistant to toxic effects of 6-OHDA on nigral dopaminergic cell counts, striatal dopamine content, and rotational behavior (Chen et al., 2013) . Conversely, transgenic over-expression of UOx exacerbated these anatomical, neurochemical, and behavioral deficits of the lesioned dopaminergic nigrostriatal pathway.
Although considerable evidence indicates that urate is a powerful direct antioxidant few studies have investigated alternative mechanisms of its protective effect. Previous findings of our group (Cipriani et al., 2012a) and others (Du et al., 2007) have suggested a prominent role of astrocytes in the neuroprotective effects of urate. We demonstrated an essential requirement for astrocytes in order for urate to fully protect dopaminergic cells (Cipriani et al., 2012a) or nigral neurons (Cipriani et al., 2012b) . We further determined that in response to urate, astrocytes release a potent neuroprotective factor, which differs from urate because it is insensitive to urate-eliminating incubation with commercial UOx enzyme. In the present study we identify and characterize Neurobiology of Disease 82 (2015) [574] [575] [576] [577] [578] [579] 
